AU2011252844B2 - Chimeric OspA genes, proteins, and methods of use thereof - Google Patents

Chimeric OspA genes, proteins, and methods of use thereof Download PDF

Info

Publication number
AU2011252844B2
AU2011252844B2 AU2011252844A AU2011252844A AU2011252844B2 AU 2011252844 B2 AU2011252844 B2 AU 2011252844B2 AU 2011252844 A AU2011252844 A AU 2011252844A AU 2011252844 A AU2011252844 A AU 2011252844A AU 2011252844 B2 AU2011252844 B2 AU 2011252844B2
Authority
AU
Australia
Prior art keywords
polypeptide
ospa
seq
borrelia
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011252844A
Other languages
English (en)
Other versions
AU2011252844A1 (en
Inventor
Brian A. Crowe
Ian Livey
Maria O'rourke
Michael Schwendinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta GmbH
Baxalta Inc
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of AU2011252844A1 publication Critical patent/AU2011252844A1/en
Application granted granted Critical
Publication of AU2011252844B2 publication Critical patent/AU2011252844B2/en
Assigned to BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC. reassignment BAXTER HEALTHCARE SA Amend patent request/document other than specification (104) Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Assigned to BAXALTA INCORPORATED, Baxalta GmbH reassignment BAXALTA INCORPORATED Request for Assignment Assignors: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2011252844A 2010-05-14 2011-05-13 Chimeric OspA genes, proteins, and methods of use thereof Ceased AU2011252844B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
US61/334,901 2010-05-14
PCT/US2011/036525 WO2011143617A1 (en) 2010-05-14 2011-05-13 Chimeric ospa genes, proteins, and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2011252844A1 AU2011252844A1 (en) 2012-11-29
AU2011252844B2 true AU2011252844B2 (en) 2014-07-03

Family

ID=44121257

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011252844A Ceased AU2011252844B2 (en) 2010-05-14 2011-05-13 Chimeric OspA genes, proteins, and methods of use thereof
AU2011252850A Ceased AU2011252850B2 (en) 2010-05-14 2011-05-13 OspA chimeras and use thereof in vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011252850A Ceased AU2011252850B2 (en) 2010-05-14 2011-05-13 OspA chimeras and use thereof in vaccines

Country Status (13)

Country Link
US (6) US8623375B2 (enExample)
EP (4) EP3650041A1 (enExample)
JP (6) JP6227407B2 (enExample)
KR (7) KR20180082633A (enExample)
CN (3) CN103108652B (enExample)
AU (2) AU2011252844B2 (enExample)
BR (2) BR112012029058B1 (enExample)
CA (2) CA2799181C (enExample)
MX (3) MX348113B (enExample)
PL (2) PL2569009T3 (enExample)
RU (2) RU2583289C2 (enExample)
SI (2) SI2569008T1 (enExample)
WO (2) WO2011143623A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180082633A (ko) * 2010-05-14 2018-07-18 박스알타 인코퍼레이티드 Ｏｓｐａ 키메라 및 백신에서 그의 용도
US20120209677A1 (en) 2010-10-20 2012-08-16 Mehta Kaushal N Person-2-person social network marketing apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
WO2013090611A2 (en) * 2011-12-13 2013-06-20 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
AU2013293448A1 (en) * 2012-07-27 2015-02-05 Baxalta GmbH Compositions comprising chimeric OspA molecules and methods of use thereof
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US20140296139A1 (en) * 2013-03-15 2014-10-02 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
US20160213766A1 (en) * 2013-09-23 2016-07-28 Ventria Bioscience, Inc. OspA Fusion Protein for Vaccination against Lyme Disease
HRP20191086T1 (hr) * 2014-01-09 2019-11-01 Valneva Austria Gmbh Mutantni ospa fragmenti i postupci i uporabe koji se na njih odnose
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
US10457721B2 (en) 2014-08-11 2019-10-29 University Of Massachusetts Anti-OSPA antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
WO2017029000A1 (en) * 2015-08-14 2017-02-23 Telefonaktiebolaget Lm Ericsson (Publ) A node and method for managing a packet data network connection
KR20190116975A (ko) * 2016-11-07 2019-10-15 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
CN112512567A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性呼吸道合胞病毒多肽
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
JP2021519599A (ja) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性ｏｓｐａポリペプチド
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
WO2021205022A1 (en) 2020-04-09 2021-10-14 Valneva Austria Gmbh Improved methods of producing a lipidated protein
MX2022012647A (es) * 2020-04-09 2023-01-16 Valneva Austria Gmbh Composiciones que comprenden tres proteinas de fusion de ospa para uso medico.
WO2022133233A2 (en) 2020-12-17 2022-06-23 Idexx Laboratories, Inc. Rocky mountain spotted fever detection and treatment
US20240368654A1 (en) * 2021-06-07 2024-11-07 University Of Massachusetts Apparatus and method for continuous production of rna
EP4490042A1 (en) 2022-03-08 2025-01-15 Equashield Medical Ltd. Fluid transfer station in a robotic pharmaceutical preparation system
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016421A2 (en) * 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992000055A1 (en) 1990-06-15 1992-01-09 Yale University Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3215109B2 (ja) 1991-02-15 2001-10-02 ユーエイビー リサーチ ファウンデーション 肺炎球菌タンパクの構造遺伝子
EP0598816B1 (en) * 1991-08-15 1999-06-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Osp a proteins of borrelia burgdorferi subgroups, encoding genes and vaccines
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
ATE263836T1 (de) 1993-11-01 2004-04-15 Brookhaven Science Ass Llc Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
JP2000505802A (ja) 1996-02-12 2000-05-16 コブラ セラピューティクス リミテッド ワクチン接種の新規な方法、ならびにそのための、第１のエピトープをコードする核酸および第２のエピトープを含有するペプチドを含むワクチン
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
CA2294701C (en) 1997-06-30 2009-09-08 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
DE60131858T2 (de) * 2000-08-18 2008-12-04 The Research Foundation Of State University Of New York Borrelia burgdorferi rekombinante genkonstrukte
EP1613641B1 (en) 2003-04-02 2009-01-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
EP1618185A4 (en) * 2003-04-16 2009-05-27 Wyeth Corp NEW IMMUNOLOGICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCOULAR DISEASE
ES2343255T3 (es) * 2004-03-24 2010-07-27 MERCK SHARP & DOHME CORP. Expresion optimizada del vph 52 l1 en levadura.
US8821893B2 (en) 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1957520A4 (en) 2005-11-29 2009-05-27 Univ Virginia Commonwealth POLYVALENTIC CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
CN101516905A (zh) 2006-09-15 2009-08-26 英特塞尔股份公司 疏螺旋体属抗原
JP5443175B2 (ja) 2007-02-22 2014-03-19 バクスター・インターナショナル・インコーポレイテッド 疎水性タンパク質を精製する方法
US9610339B2 (en) * 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
WO2009099716A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
US20110105355A1 (en) 2008-04-22 2011-05-05 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
KR20180082633A (ko) 2010-05-14 2018-07-18 박스알타 인코퍼레이티드 Ｏｓｐａ 키메라 및 백신에서 그의 용도
AU2013293448A1 (en) * 2012-07-27 2015-02-05 Baxalta GmbH Compositions comprising chimeric OspA molecules and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016421A2 (en) * 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi

Also Published As

Publication number Publication date
US20140141030A1 (en) 2014-05-22
BR112012027315B1 (pt) 2021-08-17
CN103108652B (zh) 2016-05-11
KR102222869B1 (ko) 2021-03-04
US20120020973A1 (en) 2012-01-26
US20180296656A1 (en) 2018-10-18
CA2799181A1 (en) 2011-11-17
CN103108652A (zh) 2013-05-15
KR20200024354A (ko) 2020-03-06
MX348113B (es) 2017-05-29
CN107641151A (zh) 2018-01-30
RU2583289C2 (ru) 2016-05-10
US20160235830A1 (en) 2016-08-18
RU2636455C2 (ru) 2017-11-23
KR102130584B1 (ko) 2020-07-07
US9895434B2 (en) 2018-02-20
CA2799181C (en) 2023-10-24
RU2012153752A (ru) 2014-06-20
KR20130062954A (ko) 2013-06-13
JP2020178719A (ja) 2020-11-05
BR112012029058A2 (pt) 2020-06-23
JP2016168057A (ja) 2016-09-23
CA2798331C (en) 2022-03-15
KR20200084062A (ko) 2020-07-09
KR20180031814A (ko) 2018-03-28
KR20130133120A (ko) 2013-12-06
KR20180082633A (ko) 2018-07-18
KR20190027955A (ko) 2019-03-15
KR102230562B1 (ko) 2021-03-22
WO2011143623A1 (en) 2011-11-17
US11305000B2 (en) 2022-04-19
AU2011252850B2 (en) 2016-03-17
US9334311B2 (en) 2016-05-10
MX375965B (es) 2025-03-07
AU2011252850A1 (en) 2012-11-29
EP3705133B1 (en) 2024-06-26
MX340739B (es) 2016-07-22
EP3705133A2 (en) 2020-09-09
US20140141029A1 (en) 2014-05-22
RU2012153972A (ru) 2014-06-20
CN103118701B (zh) 2017-10-24
KR102085465B1 (ko) 2020-03-05
EP3650041A1 (en) 2020-05-13
BR112012027315A2 (pt) 2016-11-16
JP2013529078A (ja) 2013-07-18
US8623376B2 (en) 2014-01-07
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
AU2011252844A1 (en) 2012-11-29
MX2012013261A (es) 2013-04-19
JP6965417B2 (ja) 2021-11-10
US8623375B2 (en) 2014-01-07
JP2018150386A (ja) 2018-09-27
BR112012027315A8 (pt) 2020-09-01
CN107641151B (zh) 2021-10-01
EP2569008B1 (en) 2019-12-25
JP2013529077A (ja) 2013-07-18
WO2011143617A1 (en) 2011-11-17
MX2012013264A (es) 2014-12-05
US9303073B2 (en) 2016-04-05
BR112012029058B1 (pt) 2022-03-29
SI2569008T1 (sl) 2020-02-28
CN103118701A (zh) 2013-05-22
JP2016171816A (ja) 2016-09-29
EP2569008A1 (en) 2013-03-20
EP3705133A3 (en) 2021-01-06
EP2569009B1 (en) 2019-10-09
PL2569009T3 (pl) 2020-06-15
RU2017138652A (ru) 2019-02-11
JP6030052B2 (ja) 2016-11-24
EP2569009A1 (en) 2013-03-20
JP6227407B2 (ja) 2017-11-08
US20110293652A1 (en) 2011-12-01
CA2798331A1 (en) 2011-11-17
RU2017138652A3 (enExample) 2021-03-15

Similar Documents

Publication Publication Date Title
US11305000B2 (en) Chimeric OspA genes, proteins and methods of use thereof
AU2018203336B2 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
HK40029362A (en) Ospa chimeras and use thereof in vaccines
RU2773402C2 (ru) Химерные гены ospa, белки и способы их применения
HK40029422A (en) Ospa chimeras and use thereof in vaccines
HK1208627B (en) Compositions comprising chimeric ospa molecules and methods of use thereof
HK1183621B (en) Ospa chimeras and use thereof in vaccines
HK1183621A (en) Ospa chimeras and use thereof in vaccines
HK1183622B (en) Ospa chimeras and use thereof in vaccines
HK1183622A (en) Ospa chimeras and use thereof in vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BAXALTA GMBH; BAXALTA INCORPORATED

Free format text: FORMER OWNER WAS: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA

MK14 Patent ceased section 143(a) (annual fees not paid) or expired